Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies
Giulio Calcagni, Rachele Adorisio, Simone Martinelli, et al.
Heart Failure Clinics (2018) Vol. 14, Iss. 2, pp. 225-235
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

2023 ESC Guidelines for the management of cardiomyopathies
Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3503-3626
Open Access | Times Cited: 1038
JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies
Hiroaki Kitaoka, Hiroyuki Tsutsui, Toru Kubo, et al.
Circulation Journal (2021) Vol. 85, Iss. 9, pp. 1590-1689
Open Access | Times Cited: 81
Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes
Emanuele Monda, Marta Rubino, Michele Lioncino, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 68
Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP)
Giuseppe Limongelli, Rachele Adorisio, Chiara Baggio, et al.
International Journal of Cardiology (2022) Vol. 357, pp. 55-71
Open Access | Times Cited: 49
Mitochondrial functions and rare diseases
Laetitia Dard, Wendy Blanchard, Christophe Hubert, et al.
Molecular Aspects of Medicine (2020) Vol. 71, pp. 100842-100842
Open Access | Times Cited: 54
Towards precision medicine in heart failure
Chad S. Weldy, Euan A. Ashley
Nature Reviews Cardiology (2021) Vol. 18, Iss. 11, pp. 745-762
Closed Access | Times Cited: 54
Hypertrophic Cardiomyopathy in RASopathies
Michele Lioncino, Emanuele Monda, Federica Verrillo, et al.
Heart Failure Clinics (2021) Vol. 18, Iss. 1, pp. 19-29
Open Access | Times Cited: 52
Genotype‐cardiac phenotype correlations in a large single‐center cohort of patients affected by RASopathies: Clinical implications and literature review
Chiara Leoni, Rita Blandino, Angelica Bibiana Delogu, et al.
American Journal of Medical Genetics Part A (2021) Vol. 188, Iss. 2, pp. 431-445
Closed Access | Times Cited: 43
MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy but Is Insufficient to Revert Pulmonary Vascular Disease
Alessandro Mussa, Diana Carli, Elisa Giorgio, et al.
Genes (2021) Vol. 13, Iss. 1, pp. 6-6
Open Access | Times Cited: 43
Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy
Áine Lynch, Mark Tatangelo, Sachin Ahuja, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 11, pp. 1035-1045
Open Access | Times Cited: 20
Genetic Testing in Hypertrophic Cardiomyopathy
Catherine G. Ireland, Carolyn Y. Ho
The American Journal of Cardiology (2024) Vol. 212, pp. S4-S13
Open Access | Times Cited: 6
Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
Andrea Gazzin, Federico Fornari, Simona Cardaropoli, et al.
Life (2024) Vol. 14, Iss. 6, pp. 731-731
Open Access | Times Cited: 6
Cardiovascular disease in Noonan syndrome
Mary Ella Pierpont, M. Cristina Digilio
Current Opinion in Pediatrics (2018) Vol. 30, Iss. 5, pp. 601-608
Closed Access | Times Cited: 59
Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome
Jovanna Dahlgren, C. Noordam
Journal of Clinical Medicine (2022) Vol. 11, Iss. 7, pp. 2034-2034
Open Access | Times Cited: 25
New prospectives on treatment opportunities in RASopathies
Bruce D. Gelb, Marielle E. Yohe, Cordula M. Wolf, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022) Vol. 190, Iss. 4, pp. 541-560
Open Access | Times Cited: 24
MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept
Dominic Chaput, Grégor Andelfinger
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 5, pp. 789-799
Closed Access | Times Cited: 5
Defining the variant-phenotype correlation in patients affected by Noonan syndrome with the RAF1:c.770C>T p.(Ser257Leu) variant
Andrea Gazzin, Federico Fornari, Marcello Niceta, et al.
European Journal of Human Genetics (2024) Vol. 32, Iss. 8, pp. 964-971
Closed Access | Times Cited: 5
Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study
Wenxiu Chan, Shiwei Yang, Jian Wang, et al.
EClinicalMedicine (2022) Vol. 49, pp. 101466-101466
Open Access | Times Cited: 21
Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?
Valentina Lodato, Giovanni Parlapiano, Federica Calì, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 2, pp. 47-47
Open Access | Times Cited: 19
Natural history and outcomes in paediatric RASopathy‐associated hypertrophic cardiomyopathy
Olga Boleti, Gabrielle Norrish, Ella Field, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 2, pp. 923-936
Open Access | Times Cited: 4
Cardiovascular aspects of Noonan syndrome and related disorders
Martin Zenker, Cordula M. Wolf
Medizinische Genetik (2025) Vol. 37, Iss. 2, pp. 113-124
Closed Access
Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy
Emanuel Kaltenecker, Julia Schleihauf, Christian Meierhofer, et al.
Cardiovascular Diagnosis and Therapy (2019) Vol. 9, Iss. S2, pp. S299-S309
Open Access | Times Cited: 31
Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib
Omid Kiamanesh, Steven C. Greenway, F. Dicke, et al.
JACC Case Reports (2024) Vol. 29, Iss. 13, pp. 102379-102379
Open Access | Times Cited: 3
Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy
Cordula M. Wolf, Martin Zenker, Olga Boleti, et al.
JACC Basic to Translational Science (2024)
Open Access | Times Cited: 3
Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome
Anna B. Meier, Sarala Raj Murthi, Hilansi Rawat, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103596-103596
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top